{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:33:39Z","timestamp":1790678019252,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,8]]},"DOI":"10.7759\/cureus.25745","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T09:28:17Z","timestamp":1654680497000},"source":"Crossref","is-referenced-by-count":15,"title":["Post-myocardial Infarction Heart Failure: A Review on Management of Drug Therapies"],"prefix":"10.7759","author":[{"given":"Gautam","family":"Swaroop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.008729","article-title":"Cardiovascular diseases in India: current epidemiology and future directions","volume":"133","author":"Prabhakaran D","year":"2016","unstructured":"Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India: current epidemiology and future directions. Circulation. 2016, 133:1605-20. 10.1161\/CIRCULATIONAHA.114.008729","journal-title":"Circulation"},{"key":"ref2","article-title":"Dilated cardiomyopathy","author":"Mahmaljy H","year":"2022","unstructured":"Mahmaljy H, Yelamanchili VS, Singhal M. Dilated cardiomyopathy. Mahmaljy H, Yelamanchili VS, Singhal M (ed): StatPearls Publishing, Treasure Island (FL); 2022."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-809657-4.10910-X","article-title":"Ischemic cardiomyopathy","volume":"145","author":"Airhart S","year":"2018","unstructured":"Airhart S, Murali S. Ischemic cardiomyopathy. Encyclopedia of Cardiovascular Research and Medicine. 2018, 145:54. 10.1016\/B978-0-12-809657-4.10910-X","journal-title":"Encyclopedia of Cardiovascular Research and Medicine"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12435","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction","volume":"36","author":"Martens P","year":"2018","unstructured":"Martens P, Beli\u00ebn H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018, 36:e12435. 10.1111\/1755-5922.12435","journal-title":"Cardiovasc Ther"},{"key":"ref5","article-title":"Ejection fraction improvement and reverse remodeling achieved with Sacubitril\/Valsartan in heart failure with reduced ejection fraction patients","volume":"7","author":"Almufleh A","year":"2017","unstructured":"Almufleh A, Marbach J, Chih S, Stadnick E, Davies R, Liu P, Mielniczuk L. Ejection fraction improvement and reverse remodeling achieved with Sacubitril\/Valsartan in heart failure with reduced ejection fraction patients. Am J Cardiovasc Dis. 2017, 7:108-13.","journal-title":"Am J Cardiovasc Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.681247","article-title":"Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter intervention and nonintervention patients in the Get With the Guidelines database","volume":"116","author":"Hiratzka LF","year":"2007","unstructured":"Hiratzka LF, Eagle KA, Liang L, Fonarow GC, LaBresh KA, Peterson ED. Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter intervention and nonintervention patients in the Get With the Guidelines database. Circulation. 2007, 116:I207-12. 10.1161\/CIRCULATIONAHA.106.681247","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.505636","article-title":"Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease","volume":"113","author":"Newby LK","year":"2006","unstructured":"Newby LK, LaPointe NM, Chen AY, et al.. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006, 113:203-12. 10.1161\/CIRCULATIONAHA.105.505636","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.601","article-title":"Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention","volume":"305","author":"Borden WB","year":"2011","unstructured":"Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011, 305:1882-9. 10.1001\/jama.2011.601","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2009.190827","article-title":"The global registry of acute coronary events, 1999 to 2009--GRACE","volume":"96","author":"Fox KA","year":"2010","unstructured":"Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA. The global registry of acute coronary events, 1999 to 2009--GRACE. Heart. 2010, 96:1095-101. 10.1136\/hrt.2009.190827","journal-title":"Heart"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/2395-5414.182988","article-title":"Heart failure in India: the INDUS (INDia Ukieri Study) study","volume":"2","author":"Chaturvedi V","year":"2016","unstructured":"Chaturvedi V, Parakh N, Seth S, et al.. Heart failure in India: the INDUS (INDia Ukieri Study) study. J Pract Cardiovasc Sci. 2016, 2:28-35. 10.4103\/2395-5414.182988","journal-title":"J Pract Cardiovasc Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90617-8","article-title":"Studies of left ventricular dysfunction (SOLVD) registry: rationale, design, methods and description of baseline characteristics","volume":"70","author":"Bangdiwala SI","year":"1992","unstructured":"Bangdiwala SI, Weiner DH, Bourassa MG, Friesinger GC II, Ghali JK, Yusuf S. Studies of left ventricular dysfunction (SOLVD) registry: rationale, design, methods and description of baseline characteristics. Am J Cardiol. 1992, 70:347-353. 10.1016\/0002-9149(92)90617-8","journal-title":"Am J Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the Capricorn randomised trial","volume":"357","author":"Dargie HJ","year":"2001","unstructured":"Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the Capricorn randomised trial. Lancet. 2001, 357:1385-1390. 10.1016\/s0140-6736(00)04560-8","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s003950070016","article-title":"MERIT-HF--description of the trial","volume":"95 Suppl 1","author":"Wikstrand J","year":"2000","unstructured":"Wikstrand J. MERIT-HF--description of the trial. Basic Res Cardiol. 2000, 95 Suppl 1:I90-7. 10.1007\/s003950070016","journal-title":"Basic Res Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"K\u00f8ber L","year":"1995","unstructured":"K\u00f8ber L, Torp-Pedersen C, Carlsen JE, et al.. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995, 333:1670-6. 10.1056\/NEJM199512213332503","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.4902","article-title":"The sleep apnea cardiovascular endpoints (SAVE) trial: rationale, ethics, design, and progress","volume":"38","author":"Antic NA","year":"2015","unstructured":"Antic NA, Heeley E, Anderson CS, et al.. The sleep apnea cardiovascular endpoints (SAVE) trial: rationale, ethics, design, and progress. Sleep. 2015, 38:1247-57. 10.5665\/sleep.4902","journal-title":"Sleep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf S","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000, 342:145-53. 10.1056\/NEJM200001203420301","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein K","year":"2002","unstructured":"Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002, 360:752-60. 10.1016\/s0140-6736(02)09895-1","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-9842(03)00112-0","article-title":"Valsartan in acute myocardial infarction (VALIANT) trial: baseline characteristics in context","volume":"5","author":"Velazquez EJ","year":"2003","unstructured":"Velazquez EJ, Pfeffer MA, McMurray JV, et al.. Valsartan in acute myocardial infarction (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail. 2003, 5:537-544. 10.1016\/s1388-9842(03)00112-0","journal-title":"Eur J Heart Fail"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1023\/a:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt B","year":"2001","unstructured":"Pitt B, Williams G, Remme W, et al.. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001, 15:79-87. 10.1023\/a:1011119003788","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al.. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020, 382:1883-93. 10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.053659","article-title":"Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF","volume":"143","author":"Jhund PS","year":"2021","unstructured":"Jhund PS, Ponikowski P, Docherty KF, et al.. Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation. 2021, 143:1962-72. 10.1161\/CIRCULATIONAHA.121.053659","journal-title":"Circulation"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation. 2021, 143:337-49. 10.1161\/CIRCULATIONAHA.120.051824","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/90486-post-myocardial-infarction-heart-failure-a-review-on-management-of-drug-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:52Z","timestamp":1707507832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/90486-post-myocardial-infarction-heart-failure-a-review-on-management-of-drug-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.25745","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,8]]}}}